Imatinib primarily acts by inhibiting :
**Core Concept**
Imatinib is a tyrosine kinase inhibitor used in the treatment of certain cancers, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). Its mechanism of action involves the inhibition of specific enzymes involved in cellular signaling pathways.
**Why the Correct Answer is Right**
Imatinib primarily acts by inhibiting the BCR-ABL tyrosine kinase, a fusion protein resulting from the Philadelphia chromosome abnormality in CML cells. This inhibition prevents the phosphorylation of downstream signaling molecules, ultimately halting the proliferation of leukemic cells. Imatinib also inhibits the activity of c-KIT and PDGFR tyrosine kinases, which are involved in the pathogenesis of GISTs.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because imatinib does not primarily act by inhibiting the mTOR pathway, which is a downstream effector of PI3K/AKT signaling.
**Option B:** This option is incorrect because imatinib does not primarily act by inhibiting the MEK/ERK pathway, which is a downstream effector of RAF signaling.
**Option C:** This option is incorrect because imatinib does not primarily act by inhibiting the STAT3 pathway, which is involved in the regulation of gene expression in response to cytokine signaling.
**Clinical Pearl / High-Yield Fact**
Imatinib is a classic example of a targeted therapy that exploits the molecular abnormalities underlying specific cancers, providing a safer and more effective treatment option for patients.
**Correct Answer: C. BCR-ABL tyrosine kinase. Imatinib primarily acts by inhibiting the BCR-ABL tyrosine kinase.**